Community seroprevalence and risk factors for SARS-CoV-2 infection in different subpopulations in Vellore, India, and their implications for future prevention.


Journal

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
ISSN: 1878-3511
Titre abrégé: Int J Infect Dis
Pays: Canada
ID NLM: 9610933

Informations de publication

Date de publication:
Mar 2022
Historique:
received: 10 11 2021
revised: 22 12 2021
accepted: 22 12 2021
pubmed: 1 1 2022
medline: 3 3 2022
entrez: 31 12 2021
Statut: ppublish

Résumé

The aim of this study was to inform public health policy decisions through the assessment of IgG antibody seroprevalence in the population and the risk factors for SARS-CoV-2 infection. The seroprevalence of IgG antibodies among different subpopulations at the end of the first and second waves of the pandemic was estimated. Various risk factors associated with seropositivity, including sociodemography, IgG antibodies against endemic human coronavirus, and vaccination status, were also assessed. For all 2433 consenting participants, the overall estimated seroprevalences at the end of first and second waves were 28.5% (95% CI 22.3-33.7%) and 71.5% (95% CI 62.8-80.5%), respectively. The accrual of IgG positivity was heterogeneous, with the highest seroprevalences found in urban slum populations (75.1%). Vaccine uptake varied among the subpopulations, with low rates (< 10%) among rural and urban slum residents. The majority of seropositive individuals (75%) were asymptomatic. Residence in urban slums (OR 2.02, 95% CI 1.57-2.6; p < 0.001), middle socioeconomic status (OR 1.77, 95% CI 1.17-2.67; p = 0.007), presence of diabetes (OR 1.721, 95% CI 1.148-2.581; p = 0.009), and hypertension (OR 1.75, 95% CI 1.16-2.64; p = 0.008) were associated with seropositivity in multivariable analyses. Although considerable population immunity has been reached, with more than two-thirds seropositive, improved vaccination strategies among unreached subpopulations and high-risk individuals are suggested for better preparedness in future.

Identifiants

pubmed: 34971822
pii: S1201-9712(21)01255-8
doi: 10.1016/j.ijid.2021.12.356
pmc: PMC8712712
pii:
doi:

Substances chimiques

Antibodies, Viral 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

138-146

Informations de copyright

Copyright © 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors have no conflicts of interest to declare.

Références

Lancet Infect Dis. 2021 Feb;21(2):203-212
pubmed: 33091374
JAMA Netw Open. 2021 Sep 1;4(9):e2124116
pubmed: 34524438
Ann Intern Med. 2020 Sep 1;173(5):362-367
pubmed: 32491919
PLoS One. 2021 Jul 29;16(7):e0255412
pubmed: 34324603
PLoS One. 2016 Aug 04;11(8):e0160706
pubmed: 27490200
Lancet. 2021 Mar 13;397(10278):1023-1034
pubmed: 33587887
Int J Infect Dis. 2021 Jul;108:145-155
pubmed: 34022338
J Infect Dis. 2005 Jun 15;191(12):2033-7
pubmed: 15897988
Clin Infect Dis. 2022 Apr 9;74(7):1208-1219
pubmed: 34216472
J Med Virol. 1979;3(4):313-20
pubmed: 113504
Cell. 2021 Apr 1;184(7):1858-1864.e10
pubmed: 33631096
Viruses. 2021 Jun 10;13(6):
pubmed: 34200766
Nat Commun. 2020 Sep 17;11(1):4704
pubmed: 32943637
Nat Commun. 2021 May 19;12(1):2938
pubmed: 34011939
Epidemiol Infect. 2021 Feb 04;149:e39
pubmed: 33536108
Viruses. 2021 Sep 07;13(9):
pubmed: 34578363
One Health. 2021 Dec;13:100283
pubmed: 34222606
Sci Rep. 2021 May 18;11(1):10551
pubmed: 34006960
BMJ. 2021 Jul 21;374:n1856
pubmed: 34290075
Lancet Reg Health Eur. 2021 May 21;5:100119
pubmed: 34557824
Pathogens. 2021 Sep 21;10(9):
pubmed: 34578254
Lancet Glob Health. 2021 Feb;9(2):e110-e111
pubmed: 33197394
Nature. 2021 Oct;598(7880):338-341
pubmed: 34438440
Int J Hyg Environ Health. 2021 Aug;237:113836
pubmed: 34481208
Emerg Infect Dis. 2021 Dec;27(12):3124-3127
pubmed: 34533453
Indian J Med Res. 2020 Feb & Mar;151(2 & 3):136-139
pubmed: 32317412
BMC Res Notes. 2021 Jul 8;14(1):262
pubmed: 34238344
Pathog Dis. 2020 Apr 1;78(3):
pubmed: 32510562
Lancet Public Health. 2021 Apr;6(4):e202-e209
pubmed: 33556328
Emerg Infect Dis. 2020 Oct;26(10):2416-2419
pubmed: 32614768
BMJ Open. 2021 Sep 23;11(9):e053791
pubmed: 34556519
J Med Virol. 1984;13(2):131-48
pubmed: 6319588
Viruses. 2021 Sep 10;13(9):
pubmed: 34578387
J Med Virol. 2021 Dec;93(12):6696-6702
pubmed: 34331713
Int J Infect Dis. 2020 May;94:44-48
pubmed: 32171952
Lancet Infect Dis. 2021 Dec;21(12):1665-1676
pubmed: 34399090
Nat Med. 2021 Jul;27(7):1205-1211
pubmed: 34002089
J Virol Methods. 2013 Feb;187(2):413-20
pubmed: 23174159
PLoS One. 2021 Nov 30;16(11):e0260164
pubmed: 34847149

Auteurs

Divya Dayanand (D)

Department of Infectious Diseases, Christian Medical College, Vellore, Tamil Nadu, India.

Indhuja Irudhayanathan (I)

Department of Infectious Diseases, Christian Medical College, Vellore, Tamil Nadu, India.

Debasree Kundu (D)

Department of Infectious Diseases, Christian Medical College, Vellore, Tamil Nadu, India.

Abi Manesh (A)

Department of Infectious Diseases, Christian Medical College, Vellore, Tamil Nadu, India.

Vinod Abraham (V)

Department of Community Health, Christian Medical College, Vellore, Tamil Nadu, India.

Kundavaram Pp Abhilash (KP)

Department of Emergency Medicine, Christian Medical College, Vellore, Tamil Nadu, India.

Binila Chacko (B)

Department of Critical Care Medicine, Christian Medical College, Vellore, Tamil Nadu, India.

Mahesh Moorthy (M)

Department of Clinical Virology, Christian Medical College, Vellore, Tamil Nadu, India.

Prasanna Samuel (P)

Department of Biostatistics, Christian Medical College, Vellore, Tamil Nadu, India.

Pimnara Peerawaranun (P)

Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.

Mavuto Mukaka (M)

Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand; Centre for Tropical Medicine and Global Health, University of Oxford, UK.

Jayaraj Joseph (J)

Department of Electrical Engineering, Indian Institute of Technology Madras, Tamil Nadu, India; Healthcare Technology Innovation Centre (HTIC), Indian Institute of Technology Madras, Tamil Nadu, India.

Mohanasankar Sivaprakasam (M)

Department of Electrical Engineering, Indian Institute of Technology Madras, Tamil Nadu, India; Healthcare Technology Innovation Centre (HTIC), Indian Institute of Technology Madras, Tamil Nadu, India.

George M Varghese (GM)

Department of Infectious Diseases, Christian Medical College, Vellore, Tamil Nadu, India. Electronic address: georgemvarghese@hotmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH